Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Moderate to severe pain where an opioid analgesic is appropriate
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE, answered by our medical review team.
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE and ACETAMINOPHEN AND HYDROCODONE BITARTRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE and ACETAMINOPHEN AND HYDROCODONE BITARTRATE. Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.